PerkinElmer bought the Swedish NIPT firm for an undisclosed amount to beef up its maternal fetal health portfolio.
The two companies are extending an existing agreement that provides for PerkinElmer to supply Agilent with chips for its 2100 Bioanalyzer system.
The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.
Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
The company's Signals for Translational provides pharmaceutical and other researchers with tools for aggregating and analyzing various kinds of data including NGS.
The company posted $563.4 million in revenues for the quarter ended Oct. 4, up from $542.0 million for the same period a year ago.
Fitch upgraded PerkinElmer's issuer default rating to BBB and cited the firm's improved operating profit and the potential for M&A.
Overall, analyst Bryan Brokmeier said he is bullish on the space in spite of uncertainty in the general global markets.
In a regulatory document, the company said the layoffs resulted from a restructuring plan to "emphasize growth initiatives."
As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.
BBC News says the uncertainty over Brexit is affecting science funding in the UK.
A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.
In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.